The contributing factors of resistance or sensitivity to epigenetic drugs in the treatment of AML

• Shohre Karimi Kelaye ^[1] ; Fatemeh Najafi ^[1] ; Bahareh Kazemi ^[1] ; Zahra Foruzandeh ^[1] ; Farhad Seif ^[2] ; Mohammad Reza Alivand ^[1] ; Saeed Solali ^[1]
  1. [1] Tabriz University of Medical Sciences

     Tabriz University of Medical Sciences

     Irán

     
  2. [2] Department of Immunology and Allergy, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 7, 2022, págs. 1250-1261
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Drug resistance is the drug-effectiveness reduction in treatment and is a serious problem in oncology and infections. In oncology, drug resistance is a complicated process resulting from enhancing the function of a pump that transports drugs out of tumor cells, or acquiring mutations in drug target. Surprisingly, most drugs are very effective in the early stages, but the response to the drug wears off over time and resistance eventually develops. Drug resistance is caused by genetic and epigenetic changes that affect cancer cells and the tumor environment. The study of inherited changes in the phenotype without changes in the DNA sequence is called epigenetics. Because of reversible changes in epigenetics, they are an attrac- tive target for therapy. Some of these epigenetic drugs are effective in treating cancers like acute myeloid leukemia (AML), which is characterized by the accumulation and proliferation of immature hematopoietic cells in the blood and bone marrow.

    In this article, we outlined the various contributing factors involved in resistance or sensitivity to epigenetic drugs in the treatment of AML